We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+15.5%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.94B
AUM Growth
+$354M
(+14%)
Cap. Flow
+$71.5M
Cap. Flow
% of AUM
2.43%
Top 10 Holdings %
Top 10 Hldgs %
43.94%
Holding
91
New
27
Increased
20
Reduced
25
Closed
12
Avg Time Held
0.9
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$85.5M |
| 2 |
uniQure
QURE
|
+$52M |
| 3 |
Labcorp
LH
|
+$50.7M |
| 4 |
Xeris Biopharma Holdings
XERS
|
+$46.9M |
| 5 |
InflaRx
IFRX
|
+$40.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$78.7M |
| 2 |
Puma Biotechnology
PBYI
|
+$74.6M |
| 3 |
Penumbra
PEN
|
+$67.6M |
| 4 |
Abbott
ABT
|
+$39.2M |
| 5 |
Regenxbio
RGNX
|
+$27.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.2% |
| 2 | Miscellaneous | 1.77% |
| 3 | Financials | 1.03% |
| 4 | Technology | 0% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
VRAY
76
DELISTED
ViewRay, Inc.
VRAY
| $168K | 0.01% |
+24,330
| New | +$177K |
2018 Q2
0 quarters
|
|
77
Accuray
ARAY
$20.2M
| $119K | ﹤0.01% |
29,000
| – | – |
2018 Q1
1 quarter
|
|
78
DELISTED
Adverum Biotechnologies
ADVM
| $118K | ﹤0.01% |
2,224
| – | – |
2016 Q2
8 quarters
|
|
|
CSLT
79
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $43K | ﹤0.01% |
+10,229
| New | +$38.4K |
2018 Q2
0 quarters
|
|
80
DELISTED
Exact Sciences
EXAS
| – | – |
-8,130
| Closed | -$328K | – |
|
|
81
Puma Biotechnology
PBYI
$549M
| – | – |
-1,095,612
| Closed | -$74.6M | – |
|
82
Universal Health Services
UHS
$11.1B
| – | – |
-67,500
| Closed | -$7.99M | – |
|
83
Viatris
VTRS
$20.8B
| – | – |
-381,000
| Closed | -$15.7M | – |
|
84
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| – | – |
-197,159
| Closed | -$5.24M | – |
|
85
DELISTED
MODEL N, INC.
MODN
| – | – |
-523,937
| Closed | -$9.46M | – |
|
|
MDRX
86
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-1,626,900
| Closed | -$20.1M | – |
|
|
PRAH
87
DELISTED
PRA Health Sciences, Inc.
PRAH
| – | – |
-245,314
| Closed | -$20.4M | – |
|
|
ARMO
88
DELISTED
ARMO BioSciences, Inc. Common Stock
ARMO
| – | – |
-298,800
| Closed | -$11.2M | – |
|
|
AVXS
89
DELISTED
AveXis, Inc. Common Stock
AVXS
| – | – |
-636,900
| Closed | -$78.7M | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q2 2018 Portfolio in Review
As of Q2 2018, Redmile Group held 91 positions worth $2.94B, up 14% from $2.59B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Redmile Group's Q2 2018 filing shows 27 new, 20 increased, 25 reduced and 12 closed positions. Its largest new stake was Clovis Oncology, Inc.: 1,758,600 shares worth $80M. The largest sale was AveXis, Inc. Common Stock, an estimated $78.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.
- Redmile Group's largest Q2 2018 buy was Clovis Oncology, Inc.: 1,758,600 shares worth $80M.
- Redmile Group added most to InflaRx in Q2 2018, an estimated $40.6M increase.
- Redmile Group's biggest Q2 2018 reduction was Penumbra, cutting an estimated $67.6M.
- Redmile Group fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $78.7M.
- Redmile Group's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2018.
- Redmile Group opened 27 new positions and closed 12 in Q2 2018.
- Redmile Group's portfolio value rose 14% quarter-over-quarter to $2.94B.
Based on Redmile Group's 13F filing for Q2 2018, filed 14 Aug 2018.